Free Trial

15 Healthcare Stocks that Analysts Love in a Post-Pandemic World - 6 of 15

 
 

Novo Nordisk A/S (NYSE:NVO)

Consensus Rating
Moderate Buy
Rating Score
2.9
Ratings Breakdown
6 Buy Ratings, 1 Hold Ratings, 0 Sell Ratings.
Consensus Price Target
$145.17 (23.9% Upside)

About Novo Nordisk A/S

Novo Nordisk A/S logoNovo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease. Read More 
 

Recent Analyst Ratings

DateBrokerageActionRatingPrice TargetDetails
9/16/2024Cantor FitzgeraldReiterated RatingOverweight ➝ Overweight$160.00 ➝ $160.00
9/9/2024Cantor FitzgeraldReiterated RatingOverweight ➝ Overweight$160.00 ➝ $160.00
8/19/2024Cantor FitzgeraldReiterated RatingOverweight ➝ Overweight$160.00 ➝ $160.00
8/8/2024BMO Capital MarketsLower Price TargetOutperform ➝ Outperform$170.00 ➝ $160.00
8/5/2024Cantor FitzgeraldReiterated RatingOverweight ➝ Overweight$160.00 ➝ $160.00
7/1/2024Cantor FitzgeraldReiterated RatingOverweight ➝ Overweight$160.00 ➝ $160.00
6/25/2024BMO Capital MarketsReiterated RatingOutperform ➝ Outperform$163.00 ➝ $163.00
6/17/2024Cantor FitzgeraldReiterated RatingOverweight ➝ Overweight$160.00 ➝ $160.00
6/10/2024ArgusBoost Price TargetBuy ➝ Buy$125.00 ➝ $160.00
5/30/2024The Goldman Sachs GroupInitiated CoverageBuy$156.00
 

War on Elon Escalates… (Ad)

A radical, potentially game-changing technology that threatens to destroy the trillion-dollar, “green energy” grift of the elites. And yet, while it threatens their wealth and power, it could be transformational for both the U.S. economy and your wealth.

One company holds a near-total monopoly on it.